Skip to content
Screener

Edwards Lifesciences EW Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Artivion logo
ArtivionAORT
$0.010.0%
ICU Medical logo
ICU MedicalICUI
$0.10.0%
Haemonetics logo
HaemoneticsHAE
$0.010.0%
Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
ITG
Integer HoldingsITGR

Other financials

Income statement

See full
Revenue$1.7B+13.6%
Gross profit$1.3B+13.5%
Operating income$513.2M+24.8%
Net income$241.9M-27.4%
EPS (diluted)$0.42-25.0%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation

See full
Market cap$51.71B+12.7%
Enterprise value$49.97B+11.0%
P/E51.5×+40.4×
P/S7.9×-0.1×

Profitability

See full
Gross margin77.8%-1.0pp
Operating margin22.3%-3.6pp
Net margin15.4%-57.5pp
FCF margin17.3%

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Edwards Lifesciences’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001099800-26-000026
Line itemMarch 31,2026December 31,2025
Commitments and contingencies (Note 12)
Stockholders' equity
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding
Common stock, $1.00 par value, 1,050.0 shares authorized, 660.0 and 658.7 shares issued, and 577.0 and 580.7 shares outstanding, respectively660.0658.7
Additional paid-in capital2,781.52,768.4
Retained earnings14,621.214,240.5
Accumulated other comprehensive loss (Note 13)(221.3)(238.3)
Treasury stock, at cost, 83.0 and 78.0 shares, respectively(7,513.9)(7,091.7)

Item 1. Financial Statements (Unaudited)

FAQ

What is Edwards Lifesciences's common stock, par value (in dollars per share)?
Edwards Lifesciences (EW) reported common stock, par value (in dollars per share) of $1.00 in Q1 2026.
How has Edwards Lifesciences's common stock, par value (in dollars per share) changed year-over-year?
Edwards Lifesciences's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $1.00 to $1.00.
What is the long-term trend for Edwards Lifesciences's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Edwards Lifesciences's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $1.00 to $1.00.

Ask your AI about Edwards Lifesciences's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude